US 12,297,243 B2
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
Peter Emtage, Lafayette, CA (US); Amy E. Gilbert, San Francisco, CA (US); Anselm Levskaya, Oakland, CA (US); Spencer Scott, San Francisco, CA (US); and Vladimir Anatolievich Slepushkin, Vallejo, CA (US)
Assigned to Cell Design Labs, Inc., Emeryville, CA (US)
Filed by Cell Design Labs, Inc., Emeryville, CA (US)
Filed on Apr. 8, 2022, as Appl. No. 17/716,630.
Application 17/716,630 is a division of application No. 16/010,805, filed on Jun. 18, 2018, granted, now 11,325,957.
Claims priority of provisional application 62/603,993, filed on Jun. 19, 2017.
Claims priority of provisional application 62/556,765, filed on Sep. 11, 2017.
Prior Publication US 2022/0372090 A1, Nov. 24, 2022
Int. Cl. C07K 14/47 (2006.01); A61K 48/00 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 5/0786 (2010.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01); A61P 35/04 (2006.01); C07K 16/46 (2006.01)
CPC C07K 14/4702 (2013.01) [A61K 48/00 (2013.01); C07K 14/4705 (2013.01); C07K 14/705 (2013.01); C07K 14/70517 (2013.01); C07K 14/71 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 19/00 (2013.01); C12N 5/0645 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); C12N 15/85 (2013.01); A61K 2039/5156 (2013.01); A61P 35/04 (2018.01); C07K 16/462 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/70 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/09 (2013.01); C07K 2319/33 (2013.01); C07K 2319/41 (2013.01); C07K 2319/50 (2013.01); C07K 2319/70 (2013.01); C07K 2319/71 (2013.01); C07K 2319/80 (2013.01); C07K 2319/95 (2013.01); C12N 2740/16043 (2013.01); C12N 2830/15 (2013.01); C12N 2830/85 (2013.01)] 9 Claims
 
1. A chimeric Notch polypeptide comprising, from N-terminal to C-terminal and in covalent linkage: a) an extracellular domain comprising a binding agent that specifically binds to an antigen; b) a Notch 2 or Notch 3 core region; c) one or more proteolytic cleavage sites; and d) an intracellular domain comprising a transcriptional regulator; and
wherein said transcriptional regulator is from the Hepatocyte Nuclear Factor (HNF) transcriptional regulator family.